Search Clinical Trials

7 Results

Completed
High-Risk Neuroblastoma Chemotherapy Without G-CSF (External Link)
Chemotherapy: CYCLE 1+2: Topotecan and cyclophosphamide Cycle 3+5: Cisplatin and Etoposide Cycle 4+6: Vincristine, Cyclophosphamide and Doxorubicin Stem cell collection: After the third cycle of chemotherapy, stem cells will be …
Baylor Role: Lead Sponsor
Completed
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (External Link)
The subject will need to have a variety of tests, exams, or procedures to find out if s/he can be on the study. The subject will also require placement of …
Baylor Role: Lead Sponsor
Completed
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (External Link)
At first the subject will have 2 cycles of cancer drugs (Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, Cyclophosphamide). The doctors call this combination of cancer drugs ABVE-PC for short. A cycle …
Baylor Role: Lead Sponsor
Completed
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury (External Link)
Traumatic brain injury (TBI) is a leading cause of death and disability among young adults. Mood disorders are the most frequent psychiatric complication of TBI, and have a large impact …
Baylor Role: Lead Sponsor
Completed
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. (External Link)
Epidemiological evidence indicates that metabolic syndrome (MS) is a strong predisposing condition for atherosclerosis. Elevation of plasma low-density lipoprotein (LDL) cholesterol(LDL-C) concentration is the most important risk factor for atherosclerosis; …
Baylor Role: Lead Sponsor
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma (External Link)
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role: Lead Sponsor
Completed
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) (External Link)
PAD occurring in the legs is a serious disease that affects about 8 million people in the United States. A person's risk for PAD increases with age but can also …
Baylor Role: Lead Sponsor